ES8601704A1 - Un polipeptido sintetico - Google Patents

Un polipeptido sintetico

Info

Publication number
ES8601704A1
ES8601704A1 ES529683A ES529683A ES8601704A1 ES 8601704 A1 ES8601704 A1 ES 8601704A1 ES 529683 A ES529683 A ES 529683A ES 529683 A ES529683 A ES 529683A ES 8601704 A1 ES8601704 A1 ES 8601704A1
Authority
ES
Spain
Prior art keywords
oncoprotein
synthetic polypeptides
determinant
synthetic
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES529683A
Other languages
English (en)
Other versions
ES529683A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES8601704A1 publication Critical patent/ES8601704A1/es
Publication of ES529683A0 publication Critical patent/ES529683A0/es
Granted legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROCEDIMIENTO DE PREPARACION DE ANTICUERPOS A PARTIR DE UN POLIPEPTIDO SINTETICO. COMPRENDE: A) FORMAR UN POLIPEPTIDO SINTETICO QUE CONTIENE DE 10 A 40 RESTOS AMINOACIDOS CORRESPONDIENDO SUSTANCIALMENTE LA SECUENCIA DE RESTOS AMINOACIDOS A UN DOMINIO DETERMINANTE DE AMINOACIDOS DE UNA ONCOPROTEINA CODIFICADA POR UN VIRUS ONCOGENICO, SIENDO DICHO DOMINIO DETERMINANTE VECINAL PERO EXCLUYENTE DEL SITIO ACTIVO DE DICHA ONCOPROTEINA; B) UNIR EL POLIPEPTIDO SINTETICO DE LA ETAPA A) A UNA MOLECULA DE PORTADOR PARA FORMAR UN ANTIGENO SINTETICO; C) DISPERSAR UNA CANTIDAD EFECTIVA DEL ANTIGENO SINTETICO DE LA ETAPA B) EN UN VEHICULO FISIOLOGICAMENTE TOLERABLE PARA FORMAR UNA VACUNA; D) INMUNIZAR UN ANIMAL HUESPED CON LA VACUNA DE LA ETAPA C); Y E) EXTRAER ANTICUERPOS, QUE INHIBEN UNA REACCION DE FOTOTRANSFERENCIA EN EL CITADO SITIO ACTIVO DE LA PRIMERA ONCOPROTEINA, ES CAPAZ DE PRECIPITARLA, E INMUNORREACCIONA CON UNA SEGUNDA ONCOPROTEINA QUE CONTIENE UN DOMINIO DETERMINANTE HOMOLOGO CON EL PRIMERO,DE DICHO ANIMAL HUESPED INMUNIZADO.
ES529683A 1983-02-14 1984-02-13 Un polipeptido sintetico Granted ES529683A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46632983A 1983-02-14 1983-02-14

Publications (2)

Publication Number Publication Date
ES8601704A1 true ES8601704A1 (es) 1985-11-16
ES529683A0 ES529683A0 (es) 1985-11-16

Family

ID=23851346

Family Applications (1)

Application Number Title Priority Date Filing Date
ES529683A Granted ES529683A0 (es) 1983-02-14 1984-02-13 Un polipeptido sintetico

Country Status (12)

Country Link
EP (1) EP0119702A3 (es)
JP (1) JPS60500716A (es)
DE (1) DE3490048T1 (es)
ES (1) ES529683A0 (es)
GR (1) GR79812B (es)
IE (1) IE840286L (es)
IL (1) IL70947A (es)
NO (1) NO844099L (es)
NZ (1) NZ207121A (es)
PT (1) PT78077B (es)
WO (1) WO1984003087A1 (es)
ZA (1) ZA84617B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
US5733738A (en) * 1983-08-17 1998-03-31 Ligand Pharmaceuticals Polypeptide-induced monoclonal receptors to protein ligands
US5030565A (en) * 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands
US4663436A (en) * 1984-04-24 1987-05-05 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4794168A (en) * 1984-04-24 1988-12-27 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
EP0177814A3 (en) * 1984-09-19 1987-12-02 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US6200764B1 (en) 1985-01-29 2001-03-13 Bayer Corporation Detection, quantitation and classification of ras proteins in body fluids and tissues
US5081230A (en) * 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US4898932A (en) * 1985-01-29 1990-02-06 E. I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5443956A (en) * 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5028527A (en) * 1988-02-22 1991-07-02 Applied Bio Technology Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
EP0203587A3 (en) * 1985-05-30 1989-08-09 F. Hoffmann-La Roche Ag Ras oncogene peptides and antibodies
EP0206065A3 (en) * 1985-06-27 1989-04-19 James R. Feramisco Method of detecting oncogene and proto-oncogene related proteins in extracellular biological fluids
JPH01500481A (ja) * 1986-05-21 1989-02-23 コールド・スプリング・ハーバー・ラボラトリー Ｒｏｓ腫瘍遺伝子をコード化するｄｎａ配列、それからコード化されたポリペプチド類及びそれに基づく診断方法及びその他の方法
US5320941A (en) * 1986-06-06 1994-06-14 Dallan Young DNA sequence encoding mas onhcogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom
JPS6374492A (ja) * 1986-09-18 1988-04-04 Hiroshi Shiyuku モノクロ−ナル抗体
DE68928470T2 (de) * 1988-08-12 1998-04-16 Ligand Pharm Inc Polypeptid-induzierte monoklonale Rezeptoren gegen Proteinliganden
US6365151B1 (en) 1996-01-19 2002-04-02 Philadelphia Health And Educational Corporation Cellular immunogens comprising cognate proto-oxogenes
GB0014870D0 (en) * 2000-06-16 2000-08-09 King S College London Peptides
WO2015103643A2 (en) * 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180499A (en) * 1971-01-27 1979-12-25 Hoffmann-La Roche Inc. Carcinoembryonic antigens
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
US4075194A (en) * 1976-12-09 1978-02-21 Yeda Research And Development Co., Ltd. Novel synthetic undecapeptide and clinical assay
US4410510A (en) * 1980-03-10 1983-10-18 Virginia Livingston-Wheeler Method for preparing a purified extraction residue fraction and its use in stimulating the immune response
US4406885A (en) * 1978-12-28 1983-09-27 Research Corporation Preparation of native oncornavirus envelope subunits and vaccines therefrom
SE447263B (sv) * 1979-04-20 1986-11-03 Bonnierfoeretagen Ab Syntetisk, antigeniskt aktiv polypeptid och antigeniskt medel innehallande nemnda polypeptid
IE56509B1 (en) * 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection

Also Published As

Publication number Publication date
PT78077B (en) 1986-03-20
IL70947A (en) 1987-11-30
EP0119702A3 (en) 1988-01-07
NZ207121A (en) 1988-05-30
PT78077A (en) 1984-03-01
ZA84617B (en) 1984-09-26
EP0119702A2 (en) 1984-09-26
JPS60500716A (ja) 1985-05-16
IE840286L (en) 1984-08-14
DE3490048T1 (de) 1985-07-11
IL70947A0 (en) 1984-05-31
WO1984003087A1 (en) 1984-08-16
ES529683A0 (es) 1985-11-16
GR79812B (es) 1984-10-31
NO844099L (no) 1984-10-12

Similar Documents

Publication Publication Date Title
ES8601704A1 (es) Un polipeptido sintetico
ATE98376T1 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
EP0651818A4 (en) IMMUNOGENIC PEPTIDES, ANTIBODIES AND USES THEREOF IN CONNECTION WITH THE BINDING OF THE CD4 MOLECULE RECEPTOR.
US5043429B1 (en) Protein fragments containing factor VIII binding domain of von willebrand factor
EP0643559A4 (en) DIPHTHERIA TOXIN RECEPTOR BINDING REGION.
ES467453A1 (es) Un procedimiento para la preparacion de hentriacontapepti- dos.
ATE290592T1 (de) Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
ATE12042T1 (de) Aminosaeurederivate und ihre therapeutische verwendung.
ATE87655T1 (de) Markierer der t-zelle aktivierung.
ATE257711T1 (de) Antagonisten der onkogenen aktivität von mdm2, und ihre verwendung in der krebsbehandlung
ES8604265A1 (es) Un metodo para preparar un peptido o una sal no toxica del mismo.
DK388384A (da) Monoklone antistoffer med specifitet for membran-associerede antigener, deres fremstilling og anvendelse
JPS5399320A (en) Method for preparing aintigens
ATE19088T1 (de) Peptid und dessen verwendung.
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
IL106271A0 (en) Tnf inhibitors
ES8501364A1 (es) Un metodo para la preparacion de nuevos polipeptidos.
ES8601483A1 (es) Un metodo de inmunoensayo para determinar la lidocaina o un derivado relacionado de la misma en una muestra a ensayar
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
EP0220865A3 (en) Lactam derivatives, their preparation and their use as hypotensive agents
Vassbotn et al. A monoclonal antibody against PDGF B-chain inhibits PDGF-induced DNA synthesis in C3H fibroblasts and prevents binding of PDGF to its receptor
ES8605769A1 (es) Un procedimiento para la preparacion de un peptido
DE69106386D1 (en) Oxysulfonylcarbamate.
EP0179412A3 (en) Antigenic peptide compounds
GR3004764T3 (es)